Q3 Earnings Forecast for AURA Issued By HC Wainwright

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Aura Biosciences in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will post earnings of ($0.47) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ FY2027 earnings at ($1.64) EPS.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09).

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Price Performance

Shares of AURA stock opened at $7.08 on Wednesday. The company has a market cap of $353.65 million, a price-to-earnings ratio of -4.09 and a beta of 0.30. Aura Biosciences has a 1 year low of $6.33 and a 1 year high of $12.38. The firm has a fifty day moving average price of $7.64 and a 200-day moving average price of $8.66.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its position in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after buying an additional 43,897 shares during the last quarter. State Street Corp increased its holdings in Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after acquiring an additional 26,841 shares during the last quarter. Geode Capital Management LLC lifted its stake in Aura Biosciences by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after purchasing an additional 39,379 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Aura Biosciences during the 3rd quarter valued at about $1,037,000. Finally, Franklin Resources Inc. grew its position in shares of Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after purchasing an additional 215,597 shares in the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 23,045 shares of company stock worth $177,242. Corporate insiders own 5.40% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.